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Abstract 
Lewy body dementia is the second most common neurodegenerative dementia and is 
pathologically characterized by α-synuclein positive cytoplasmic inclusions, with varying 
amounts of amyloid-β (Aβ) and hyperphosphorylated tau (tau) aggregates in addition to 
synaptic loss. A dysfunctional ubiquitin proteasome system (UPS), the major proteolytic 
pathway responsible for the clearance of short lived proteins, may be a mediating factor of 
disease progression and of the development of α-synuclein aggregates. In the present study, 
protein expression of a key component of the UPS, the RPT6 subunit of the 19S regulatory 
complex was determined. Furthermore, the main proteolytic-like (chymotrypsin- and PGPH-) 
activities have also been analysed. The middle frontal (Brodmann, BA9), inferior parietal 
(BA40) and anterior cingulate (BA24) gyrus’ cortex were selected as regions of interest from 
Parkinson’s disease dementia (PDD n=31), dementia with Lewy bodies (DLB n=44), 
Alzheimer’s disease (AD n=16) and control (n=24) brains. Clinical and pathological data 
available included the MMSE score. DLB, PDD and AD were characterized by significant 
reductions of RPT6 (one-way ANOVA, p < 0.001; Bonferroni post hoc test) in prefrontal 
cortex and parietal cortex compared with controls. Strong associations were observed 
between RPT6 levels in prefrontal, parietal cortex and anterior cingulate gyrus and cognitive 
impairment (p = 0.001, p = 0.001, and p = 0.008 respectively). These findings highlight the 
involvement of the UPS in LBD and indicate that targeting the UPS may have the potential to 
slow down or reduce the progression of cognitive impairment in DLB and PDD.  
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Introduction  
 
Lewy body diseases (LBD) include dementia with Lewy bodies (DLB), Parkinson's disease 
(PD) and PD dementia (PDD). DLB and PDD account for 10-20% of dementias [1]. 
Clinically, both conditions are characterised by progressive cognitive decline, visual 
hallucinations, fluctuating cognition and parkinsonism. The neuropathological hallmark 
lesions include α-synuclein aggregates which present as intracytoplasmic Lewy bodies and 
Lewy neurites in axons and dendrites in cortical and limbic areas (DLB and PDD) as well as 
in the substantia nigra (PDD and PD). In addition, ubiquitin-containing inclusions [2, 3] and 
amyloid-β (Aβ) plaques are frequently seen. The neurochemical features of DLB and PDD 
include severe loss of cholinergic neurons within the nucleus basalis magnocellularis [4] and 
extensive cortical and thalamic cholinergic deficits [5-7].  Similar to Alzheimer’s disease 
(AD), no disease modifying treatments have been discovered for LBDs.   Cholinesterase 
inhibitors [8, 9] and memantine [10] offer symptomatic benefit, but the development of 
therapies targeting the mechanisms of α-synuclein accumulation and aggregation in the 
cortex are at a preliminary stage. 
The ubiquitin-proteasome system (UPS), the major proteolytic pathway responsible for the 
clearance of short lived proteins and the major non-lysosomal pathway for α-synuclein 
degradation (Bennett et al, 1999), has in particular been a focus of research interest.  
Structurally, the 26S proteasome consists of a 20S proteolytic core and a 19S regulatory 
complex, composed of α and β subunits organized in four rings of seven subunits, three of the 
β-subunits in each ring containing the active sites at which proteolysis of substrate proteins 
occurs (Baumeister et al, 1998). Each of these three subunits has distinct proteolytic 
activities, described as chymotrypsin-like, trypsin-like, and peptidyl glutamyl-peptide 
hydrolytic (PGPH) activities (Rivett, 1989). Together, these activities represent the best 
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characterised peptidase activities although activities associated with cleavage of branched-
chain, aromatic and small neutral amino acids have been reported (Orlowski, 1993). The α 
subunits are involved in tethering of the 19S regulatory complex to the 20S proteasome and 
serve to maintain the structural stability of the 20S proteasome (Tai and Schuman, 2008). 
ATPase sub-units (RPT1-6) are essential for cellular survival; furthermore, the ATPase sub-
units are hypothesized to recognize the polyubiquitin degradation signal and to unfold the 
protein substrates for their degradation by the 20S core, thereby controlling the access of 
substrates to the proteolytic core [11, 12]. The 20S catalytic core alone has a closed gate and 
requires an activator to regulate its protease activity. 
Dysfunction of the 26S proteasome has been increasingly recognised as playing a 
fundamental role in the pathogenesis of many neurodegenerative disorders [13, 14]. 
Neurodegenerative disorders share a common feature which is the accumulation of misfolded 
proteins in the form of insoluble protein aggregates or inclusion bodies. Each of these 
aggregates has a specific protein component depending on the disease, such as α-synuclein in 
Lewy bodies or hyperphosphorylated tau in neurofibrillary tangles in AD. However, 
irrespective of the characteristic protein aggregate, ubiquitin has been identified as an 
additional component of inclusion bodies in many neurodegenerative diseases [15], 
suggesting that polyubiquitination and impairment of the UPS is generally involved in 
inclusion body formation. In particular in LBDs, several lines of evidence support the 
involvement of the UPS and post-mortem studies using PD cohorts have shown a reduction in 
proteasomal activity in the substantia nigra [16]. Preliminary studies have also identified 
proteasomal abnormalities in cortical regions of DLB subjects [17]. Moreover, inhibition of 
proteasome activity in neuronal cell lines resulted in accumulation of ubiquitinated proteins 
[18] and α-synuclein aggregation [19, 20]. Finally, aggregated α-synuclein binds strongly to 
the 19S component and inhibits the UPS [21]. 
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Studying the UPS is essential to have a better understanding of these specific pathways to 
enable the development of targeted therapies. We therefore investigated the protein 
expression of a key component of the UPS, the RPT6 subunit of the 19S regulatory complex 
and relevant proteasome activities (chymotrypsin-like and PGPH-like) in individuals with 
DLB, PDD and AD in comparison to controls. The relationship between these changes and 
cognitive impairment was also explored. RPT6 is the best characterised of the ATPase 
proteasome subunits and has been linked by several studies to neurodegeneration, hence its 
use in our study as the representative proteasome subunit. 
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Methods and Materials 
 
Participants, diagnosis and assessment 
 
Post-mortem brain tissue was obtained from: University Hospital Stavanger (Norway), the 
MRC London Neurodegenerative Diseases Brain Bank, the Thomas Willis Oxford Brain 
Collection and the Newcastle Brain Tissue Resource. The UK brain banks are part of the 
Brains for Dementia Research Network. All participants gave informed consent for their 
tissue to be used in research and the study had ethics approval from the National Research 
Ethics Service (08/H1010/4). Table 1 shows the demographic details of the patients and 
controls. Biochemical and histopathological analysis was undertaken on prefrontal cortex 
(BA9), anterior cingulate gyrus (BA24) and parietal cortex (BA40). BA9 was selected due to 
its proposed role in executive function and cognition [22], decline of which is characteristic 
of DLB and PDD. BA24 was selected since α-synuclein pathology in BA24 develops early in 
DLB and PDD [23] while BA40 was selected because it shows severe AD and comparatively 
low LBD pathology, respectively [24]. 
 
Neuropathological assessment was performed according to standardised neuropathological 
scoring/ grading systems, including phases of amyloid-β (Aβ) deposition (Aβ-phases), 
neurofibrillary tangle Braak stages, Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) scores, Newcastle/ McKeith Criteria for Lewy body disease and National 
Institute on Aging - Alzheimer’s Association (NIA-AA) guidelines [1, 25-28]. Controls were 
neurologically normal, with only mild age associated neuropathological changes (e.g., 
neurofibrillary tangle Braak stage ≤II) and no history of neurological or psychiatric disease.  
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Cognitive impairment data consisted of the last Mini-Mental State Examination (MMSE) 
scores a maximum of two years prior to death [29]. Patients and controls were categorised 
according to cognitive impairment in the following manner; ‘unimpaired cognition’ – for 
individuals classified by the brain bank(s) as being clinical controls, ‘neurodegenerative 
disease without dementia’ – for individuals with MMSE scores of 25 to 30 and no 
antemortem diagnosis of dementia, ‘mild dementia’ – for individuals with MMSE scores 
from 17 to 24, ‘moderate dementia’ – for individuals with MMSE scores of 10 to 16, ‘severe 
dementia’ for individuals with MMSE scores of 9 or less [30]. Table 2 shows how the clinical 
diagnoses were divided between these categories. Final diagnoses for patients are clinico-
pathological consensus diagnoses incorporating the one-year rule to differentiate DLB and 
PDD [1]. 
 
Preparation of tissue samples for western blotting 
 
Preparation of tissue for western blotting was performed as previously described [30]. 
Briefly, cortical grey matter was dissected free of the meninges and white matter at 0–4°C. 
Approximately 200 mg tissue was homogenized in 4 ml ice-cold buffer containing 50mM 
tris-HCL, 5mM EGTA, 10mM EDTA, ‘complete protease inhibitor cocktail tablets’ (Roche, 
1 tablet per 50ml of buffer), and 2μg/ml pepstatin A dissolved in ethanol:DMSO 2:1 (Sigma). 
An IKA Ultra-Turrax mechanical probe (IKA Werke, Germany) was used for 
homogenisation. Aliquots were immediately frozen on dry ice and stored at −70°C. Protein 
concentration was assessed in triplicate using the Coomassie (Bradford) Protein Assay Kit 
(Thermo Scientific, USA); briefly 10μl of crude homogenate was diluted 1:50 and read in 
triplicate at 595nm using a FlexStation 3 (Molecular Devices). 
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Western Blotting 
 
Western blotting was undertaken as previously described [30]. Briefly, crude brain 
homogenate was diluted 4:5 with 5x sample buffer (Genscript MB01015, USA), boiled for 5 
minutes then stored at -20°C. Samples were loaded at 20μg/ml total protein on 10% SDS-
polyacrylamide gel for protein separation, transferred to nitrocellulose membrane  
(Hydrobond C, Amersham Biosciences, Amersham, UK), and probed with Proteasome 19S 
ATPase subunit RPT6 (p45-110, Enzo Life Sciences, Exeter, UK, 1:2000), Proteasome 20S 
α3 subunit (MCP257, Enzo Life Sciences, Exeter, UK, 1:2000) Proteasome 20S α6 subunit, 
(MCP20, Enzo Life Sciences, Exeter, UK, 1:2000). Bands were detected using an Odyssey 
infrared fluorescent scanner, the integral of intensity quantified using Odyssey infrared 
imaging systems application software version 3.0.16 and expressed as ratios to rat cortex run 
on the same gel in arbitrary units. All samples were run in duplicate. 
 
 
Proteasome enzyme activity assay 
Proteasome activity was assessed in post-mortem brain tissue using fluorogenic synthetic 
peptide substrates [for chymotrypsin-like activity, Suc-Leu-Leu-Val-Tyr-AMC; for PGPH-
like activity, Z-Leu-Leu-Glu-AMC] as described previously [31]. In brief, frozen grey matter 
from patient and control subjects were immediately homogenised by ultra turrax in ice-cold 
buffer (50 mM Tris-HCl, 1 mM EDTA, 10% glycerol, 2 mM ATP, 0.5 mM DTT, pH 7.5). 
Protein concentration was determined by the Bradford method. Brain lysates (100 μl per 
well) containing 1 mg/ml of protein were incubated with 1 l (5 mM substrate III, Suc-Leu-
Leu-Val-Tyr-AMC) or 10 l (1 mM substrate II, Z-Leu-Leu-Glu-AMC)1 mM PGPH 
substrates for 60 min at 37 °C. Measurements were performed in 96 well plates (total volume 
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100 μl per well) and all samples were assayed in triplicate for both activities. In a separate 
well, lysates were also pre-incubated with 5 mM carbobenzoxyl-leucinyl-leucinyl-leucinal 
(MG-132; a final concentration of 50 μM for chymotrypsin-like activity) and 150 μM for 
PGPH-like activity, or 100% DMSO for 30 min at room temperature. The background 
fluorescence values obtained by incubating the lysates with the proteasome inhibitors were 
subtracted from activity values. Proteasomal activity rates are expressed as fluorescence units 
(FU)/mg protein/hour. The substrate hydrolysis was determined by measuring the 
fluorescence intensity of the AMC released using a FlexStation 3 (Molecular Devices LTD, 
UK) at an emission wavelength of 355 nm and an excitation wavelength of 460 nm. The 
specificity of the proteasomal assay was confirmed by the ability of the proteasome inhibitor 
to inhibit chymotrypsin-like and PGPH-like activities.  
 
 
Statistical preparation and analysis 
 
Statistical analysis of the biochemical data was undertaken as described previously [30, 32]. 
The normality of the data for each protein was determined using the Shapiro-Wilk test and 
normalised where necessary. In each case, the protein values were subsequently expressed as 
residuals (unstandardised) created from the multivariable regression analysis, to eliminate the 
confounding effect of the demographic variables (gender, post mortem delay (PMD), age at 
death, length of brain storage) on the protein values. RPT6 values were significantly 
predicted by age at death (in BA9 and 40) and PMD (in BA24 and 40), PGPH-like activity 
values were significantly predicted by PMD in BA40, and so a residual variable was created 
for this protein and this activity to statistically remove this effect. This variable was then 
normalised using a log10 transformation. We tested for differences in protein levels between 
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groups using one-way ANOVA and Bonferroni post- hoc test. Intercorrelations of 
neurochemical variable and correlations with demographic and clinical features were 
examined using Pearson product moment (r) and regression analysis. Statistical analyses were 
conducted using SPSS version 20. 
 
 
Results 
Patient demographic data 
Demographic variables for the study cohort are summarised in Table 1. There were no 
significant differences in PMD, tissue pH or gender between diagnostic groups. AD patients 
were significantly older at death (one-way ANOVA F(3;126) = 6.044, p = 0.001) than 
controls (p = 0.001), patients with DLB (p = 0.008) or PDD (p = 0.001). Therefore residuals 
were calculated. 
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Differences in the levels of 19S ATPase RPT6 proteasome sub-unit between diagnostic 
groups. 
 
Significant reductions in RPT6 proteasome sub-unit were detected in the prefrontal cortex 
(BA9) in DLB (-17%, p = 0.001), PDD (-21%, p = 0.001) and AD (-22%, p = 0.001) 
compared with controls (one-way ANOVA, F = 24.303, d.f. = 3, 119; p = 0.001; Bonferroni 
post hoc test) (Figure 1). In BA 40 there was a significant reduction in RPT6 proteasome sub-
unit in DLB (-14%, p = 0.001) and AD (-23%, p = 0.001) compared with controls (one-way 
ANOVA, F = 16.33, d.f. = 3 and 121, p = 0.001; Bonferroni post hoc test).  There was no 
significant alteration in the level of RPT6 protein in patients with PDD compared with the 
control groups (Figure 1). Furthermore, significant reductions in RPT6 sub-unit levels were 
seen in DLB (-13%, p = 0.001) and AD (-13%, p = 0.001) compared with the PDD. In BA24 
mean RPT6 levels were significantly elevated in patients with PDD by 15%, p = 0.001 
compared with AD and DLB groups (one-way ANOVA F = 13.5, d.f. = 3 and 113, p = 0.001; 
Bonferroni post hoc test).  The post hoc test revealed that there was no significant difference 
between the control and PDD groups (p>0.05) (Figure 1).  
 
 
 
 
 
 
Assessment of PGPH-like proteasome activity 
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In BA9, a significant reduction in PGPH-like activity was seen in AD patients compared with 
controls (-23%, p = 0.012) (one-way ANOVA, F = 3.816, d.f. = 3 and 34, p =0.019; 
Bonferroni post hoc test).  There was no significant difference between DLB (-13%, p > 0.05) 
and PDD (-14%, p > 0.05) groups compared to controls (Figure 2). 
In BA40, there was a significant reduction in PGPH-like activity in the AD (-45%, p = 
0.001), DLB (-39%, p = 0.001), and PDD (-29%, p = 0.02) groups compared with controls 
(Figure 2). The differences between the patient groups and the control were statistically 
different (one-way ANOVA, F = 10.263, d.f. = 3 and 42, p = 0.001; Bonferroni post hoc test)  
In BA24, there was a significant reduction in PGPH-like activity in DLB (-28%, p = 0.013), 
PDD (-64%, p = 0.001) and AD (-62%, p = 0.001) groups compared with control subjects 
(one-way ANOVA, F = 23.087, d.f. = 3 and 39, p = 0.001; Bonferroni post hoc test). The 
reduction in PGPH-like activity in PDD (-51%, p = 0.002) and AD (-47%, p = 0.004) was 
also significant different compared with DLB (Figure 2). 
 
Assessment of chymotrypsin-like proteasome activity 
 
 
In BA9, chymotrypsin-like activity was significantly reduced in PDD (-27%, p = 0.004), 
DLB (-24% p = 0.013), and AD (-38%, p = 0.001), compared with control values (one-way 
ANOVA, F = 7.897, d.f. = 3 and 34, p = 0.001; Bonferroni post hoc test) (Figure 5). 
Chymotrypsin-like activity was lowest in the AD group compared with DLB and PDD; 
however, there were no significant differences among the three groups, PDD, DLB, or AD. In 
BA40 analysis of data indicated a significant reduction in chymotrypsin-like activity in the 
AD, DLB, and PDD (1415.85 ± 9.9, n = 12, 1453.09 ± 11.77, n = 9 and 1436.88 ± 20.61, n = 
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10) groups compared with the control groups (1568.53 ± 10.2, n = 13) (one-way ANOVA, F 
= 30.033, d.f. = 3 and 40, p = 0.001; Bonferroni post hoc test).  
In BA24, chymotrypsin-like activity was found to be significantly lower in PDD (878 ± 62, n 
= 9) and AD (906 ± 72, n = 9) samples compared with both control (1100 ± 39, n = 13) and 
DLB (1027± 23, n = 12) subjects (one-way ANOVA, F = 4.663, d.f. = 3 and 39, p = 0.007; 
Bonferroni post hoc test). 
Correlations between proteasome activity and expression level of RPT6 subunit  
To test whether or not proteasome activity was associated with the protein levels of the 
proteasome subunits, Spearman’s rank correlation was determined between PGPH- and 
chymotrypsin-like activities, and the semi-quantitative protein values of RPT6. In BA9, 
significant positive correlations were found between RPT6 and both chymotrypsin-like 
activity (Rs .418, p = .009, n = 38) and PGPH-like activity (Rs .363, p = .025, n = 38), while 
in BA40, there was a significant positive correlation with only chymotrypsin-like activity (Rs 
.409, p = .006, n = 44). 
 
Reduction in RPT6 were associated with cognitive impairment 
  
The reduced levels of RPT6 detected in BA9 were found to be associated with cognitive 
impairment (figure 4A, R
2
 = 0.297, beta = −0.545, degree of freedom [df] = 1, 102, t = 
−6.571, p = 0.001), and this analysis included all control, DLB, PDD and AD subjects. In 
addition, in pairwise comparisons, patients with mild dementia had mean RPT6 levels that 
were significantly lower than individuals with unimpaired cognition (41%, p = 0.001), and 
RPT6 levels were significantly lower in people with moderate dementia (both 20%, p = 
0.001) and with severe dementia (both 23%, p = 0.001) in BA9 compared with controls. 
Reduced levels of RPT6 in BA40 were also associated with cognitive impairment (Fig. 4C, 
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R2 = 0.180, beta = −0.425, df = 1, 105, t = −4.807, p = 0.001) according to regression 
analysis of all controls and dementia patients. In BA40 RPT6 levels were significantly lower 
in people with moderate cognitive impairment (both 10%, p = 0.033) and with severe 
cognitive impairment (both 19%, p = 0.001) compared with controls. The association 
between reduced levels of RPT6 and cognitive impairment in BA24 was weaker (Fig. 4B R
2
 
= 0.04, beta = −0.206, df = 1, 99, t = −2.09, p = 0.039) and not significantly different between 
people with different severities of cognitive impairment (one-way ANOVA p > 0.05).  
 
Reduced proteasome activity is associated with cognitive impairment 
  
Chymotrypsin-like and PGPH proteasome activities had a significant inverse association with 
cognitive impairment in BA9 (according to regression analysis of all dementia patients and 
controls) (figure A and D, R
2
 = 0.337, beta = −0.581, [df] = 1, 29, t = −3.84, p = 0.001, R2 = 
0.275, beta = −0.524, [df] = 1, 29, t = −3.315, p = 0.002), in BA24 (figure B and E, R2 = 
0.151, beta = −0.388, [df] = 1, 38, t = −2.599, p = 0.013, R2 = 0.371, beta = −0.609, [df] = 1, 
38, t = −4.733, p = 0.001) and in BA40 (figure C and F, R2 = 0.531, beta = −0.728, [df] = 1, 
40, t = −6.72, p = 0.001, R2 = 0.217, beta = −0.466, [df] = 1, 38, t = −3.244, p = 0.002). 
Pairwise comparisons in BA9 indicated high chymotrypsin-like activity in the control 
compared with moderate (p = 0.014) and severe scores (p = 0.01) (one-way ANOVA F = 
5.009, d.f. = 4 and 26, p = 0.004; Bonferroni post hoc test). The difference in PGPH-like 
activity between cognitive impairment groups was significant between individuals with 
unimpaired and moderately impaired cognition (one-way ANOVA F = 3.616, d.f. = 4 and 26, 
p = 0.004; Bonferroni post hoc test). In BA24 there was no significant difference in 
chymotrypsin-like activity in unimpaired cognition group compared with all other groups. 
The difference in PGPH-like activity between cognitive impairment groups was significantly 
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different between unimpaired cognition groups and MCI (p = 0.03), mild (p = 0.024), 
moderate (p = 0.001) and severe scores (p = 0.001) (one-way ANOVA F = 9.839, d.f. = 4 and 
35, p = 0.001; Bonferroni post hoc test).  In BA40 the level of chymotrypsin-like activity was 
significantly higher in the unimpaired cognition group compared with MCI (p = 0.001), mild 
(p = 0.001), moderate (p = 0.001) and severe scores (p = 0.001) (one-way ANOVA F = 
21.845, d.f. = 4 and 37, p = 0.001; Bonferroni post hoc test). PGPH-like activity was 
significantly higher between unimpaired cognition group compared with MCI (p = 0.02), 
mild (p = 0.001), moderate (p = 0.001) and severe scores (p = 0.034) (one-way ANOVA F = 
8.851, d.f. = 4 and 35, p = 0.001; Bonferroni post hoc test). 
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Discussion:  
 
The main finding of the present study was the reductions of the RPT6 ATPase 19S regulatory 
subunit in DLB and AD in the frontal lobe neocortical area BA9, anterior cingulate gyrus 
BA24 and parietal cortex BA40. Furthermore, the reduction in RPT6 levels was associated 
with changes in two proteasome proteolytic activities. Finally, both measurements were 
associated with cognitive scores prior to death. In this study, for the first time, an association 
between cognitive decline and both the reduction of RPT6 and the proteolytic activity of the 
proteasome has been demonstrated.  
RPT6 is one of the six ATPase subunits (RPT 1–6) of the 19S regulatory complex; it is a 
45kDa subunit. Degradation of ubiquitinated substrate proteins by the 26S proteasome is 
dependent upon ATP [33], which binds to the six ATPase subunits of the 19S regulatory 
complex. All six of the ATPase subunits contain the same substantial main functional 
domains: an N-terminus coiled-coil domain important for formation of the 19S base, and a C-
terminus ATPase domain that is involved in ATP-dependent substrate unfolding and 20S CP 
opening [34]. These ATPases provide the energy necessary for the degradation of multi-
ubiquitin conjugated proteins by the 26S proteasome, and it is also believed that ATPase 
subunits participate in the substrate-unfolding step of the degradation pathway [35].  
It has been shown previously that the 19S RPT6 expression level decreased when α-synuclein 
was increased in mouse PD models [36] and a study of 9 PD, 7 PDD and 9 controls revealed 
a decrease in the 19S RPT3/S6 subunit in the inferior frontal gyri of PDD although the 
expression was similar in control and PD [37]. Inactivation of the 19S regulatory particle 
(RPT2) subunit prevented the formation of the 26S proteasome, leaving the 20S proteasome 
subunit, which is ubiquitin-independent, unaffected [38]. Therefore, the reduction in RPT6 
subunit expression identified in DLB, PDD and AD patients in three brain regions and the 
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associated reduction in proteasome activity confirms and extends previous studies by 
demonstrating this phenomenon in the human brain and suggests that reduced subunit 
expression may directly lead to proteasome impairment. The reason for the reduction in 
RPT6 ATPase subunit expression remains unexplained. It is possible that the reduction could 
be related to oxidative stress; indeed, proteasome subunits were demonstrated to be sensitive 
to oxidative stress [39, 40]. Furthermore, Sun et al. reported that proteasome subunits (RPT5, 
Rpn10 and Rpn2) can be cleaved by caspase-3 following caspase activation during apoptosis; 
they found decreased proteasome activity to be associated with the cleavage of these subunits 
[41]. 
RPT6 phosphorylation enhances proteolysis by promoting the assembly of the 26S 
proteasome, and RPT6 dephosphorylation promoted the dissociation of 26S into 19S and 20S 
components [42]. It is proposed that the reduction of proteasome activity is due to the 
decrease in the RPT6 level as there was a correlation between lower RPT6 protein levels and 
proteasome activity in BA9 and BA40. It could also be due to the important role of RPT6 in 
promoting the activity of proteasomes. The reduction of the proteolytic activity could also 
arise from the blockading of the entry pore to the 20S proteasome by protein aggregates, such 
as α-synuclein, which may in turn impede degradation of this and other proteins [43-45]. 
Inhibition of the 26S proteasome with soluble oligomeric species of mutant and wild-type α-
synuclein in PC12 cells has been demonstrated [43]. It is clear that these oligomers are 
degraded by the proteasomes, as they accumulate when proteasome function is inhibited. 
Proteasome inhibitors have been reported to induce α-synuclein aggregation and Lewy body-
like inclusions, leading to neuronal loss among in vitro and in vivo models [38]. However, it 
is not clear whether the aggregation results from the impairment of the proteasomes or vice 
versa [46]. Results from experimental studies have indicated that inhibition of the 
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proteasomes causes the formation of aggregates [38, 47] and protein aggregation inhibits the 
proteasome activity [43].    
In this study we found a reduction in RPT6 and the proteasome activity in relation to 
cognitive decline. It is not clear how proteasome impairment, specifically reduction in RPT6, 
could result in cognitive impairment. A possible mechanistic explanation for this is that, the 
proteasome activity is regulated by protein such as Calcium/calmodulin-dependent protein 
kinase II (CaMKII), which plays an essential role in long-term synaptic plasticity and 
cognitive function [48, 49]. Consistent with this, Jarome et al. showed that phosphorylation 
of RPT6 by CaMKII increased proteasome activity in vivo and proteasome activity was 
necessary for long-term memory function [50, 51]. Reductions in CaMKII affect signalling 
pathways, including phosphorylation of RPT6, and thus the proteasome activity [50, 51], 
which could in turn impair synaptic plasticity and contribute to cognitive dysfunction.  
CaMKII has been shown to mediate proteasome activity and act as a scaffold to recruit 
proteasomes to dendritic spines and regulate its activity by phosphorylation of the RPT6 
subunits [52]. Activation of NMDA receptors has been shown to induce this movement of the 
proteasome to the dendritic spine compartment [53].  
In view of the above, our data strongly suggest that proteasome activation may be a target for 
disease modification of both DLB and PDD. In support of this view, compounds which 
enhance proteasome activity have been suggested to be neuroprotective. For example, pre-
treatment with trans-retinoic acid protected against cell death induced by epoxomicin (a 
proteasome inhibitor) in SH-SY5Y cells [54]. Furthermore, altered insulin and insulin-like 
growth factor (IGF-1) signalling have been reported to influence the proteasome activity [55, 
56], and both insulin and IGF-1 receptor expression was reduced in DLB [57].  Supporting 
this, treatment with IGF-1 prevented the apoptotic effects of epoxomicin on SH-SY5Y cells 
[58]. Therefore, compounds that are able to ameliorate insulin signalling may have disease-
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modifying activity in PDD and DLB. Of these, the glucagon-like pepide-1 (GLP-1) analogues 
are the most clinically advanced. These synthetic GLP-1 analogues such as exendin-4, 
liraglutide, albiglutide and lixisenatide are resistant to degradation by dipeptidyl peptidase, 
pass the blood--brain barrier similar to GLP-1, (except for albiglutide), and bind to the GLP-1 
receptor, bringing about an increase in insulin biosynthesis and release [59]. Both exenatide 
(exendin-4) and liraglutide are currently in phase II clinical trials for the treatment of AD 
(NCT01255163 and NCT01843075 respectively; [60]. Furthermore, exenatide is currently in 
a phase II trial for the treatment of PD (NCT01971242).  These studies suggest that 
compounds acting on GLP-1 receptors may translate well for the treatment of people with 
DLB or PDD. It is noteworthy that both retinoic acid and GLP-1 analogues have previously 
been suggested from drug repositioning studies for AD [61]. Many of these compounds have 
additional mechanisms of action, including lowering plasma glucose concentrations for GLP-
1 analogues. However, key candidate therapies are likely to involve more than one 
mechanism of action.    
The strengths of this study are the large number of LBD cases, our access to all the clinical 
data and the number of projects undertaken on the same cohort, which provide chemical 
information on synaptic functions in addition to pathological and clinical data [62-67]. 
Furthermore, this study examined three brain regions and compared the results from each of 
the regions separately to determine whether the biochemical changes are specific to a 
particular brain area or if all of the regions have the same alteration. However, despite these 
advantages, there are also a number of limitations regarding the use of post-mortem tissues 
which need to be taken into consideration. These include ante-mortem factors such as 
medication history, meaning we could not identify whether or not the medication had any 
effect on our observations. Post-mortem factors, including post-mortem delay, and the 
handling and storage of tissue are further problems that also should be addressed when 
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performing studies with post-mortem tissue reviewed in [68]. Furthermore, alteration of brain 
tissue pH, as a consequence of agonal state can affect sample quality for genetic and 
biochemical measurements. These factors were taken into consideration when planning the 
studies in this study. Post-/ante-mortem factors for controls, DLB, PDD and AD were 
matched as closely as possible for PMD and pH, and any relationships found between protein 
measurements and demographics/post-mortem factors were controlled for via the creation of 
unstandardized residuals. 
In conclusion, the present study has demonstrated that, in PDD, DLB and AD, the activity of 
the RPT6 ATPase 19S regulatory subunit of the proteasome is decreased and associated with 
cognitive decline. The present study provides support for enhancement of the proteasome 
activity as a therapeutic target and current leading candidate are GLP-1 analogues. 
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Tables and Figures 
 
Table 1: Patient demographic data. 
Data are means ± SD age in years; PMD = post-mortem delay; DLB = dementia with Lewy 
bodies; PDD = Parkinson’s disease dementia; AD = Alzheimer’s disease. PMD and pH were 
not significantly different between the groups in the one-way analysis of variance (ANOVA) 
(p < 0.05) 
  
Diagnosis Gender 
(M/F) % 
Age at 
death 
(mean) 
PMD 
(mean 
hours) 
pH (mean) MMSE (last 
assessment) 
Control (25) 60/40 79.7 ± 7.6 39.1 ± 22.9 6.47 ± 0.28 n/a 
PDD (34) 53/47 79.9 ± 6.0 33.5 ± 15.6 6.44 ± 0.34 13 (0-27) 
DLB (55) 58/42 81.7 ± 6.5 41.3 ± 28.0 6.37 ± 0.41 13 (0-30) 
AD (16) 31/69 88.0 ± 7.8 34.9 ± 23.9 6.30 ± 0.33 10.5 (0-19) 
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Table 2: Demographic data for cognitive impairment categories. 
MMSE 
Category 
Diagnosis Gender Age at 
Death 
Control (1) Control 
n=25, PDD 
n=1 
m=61.5% 79.2±1.6 
MCI (2) DLB n=5, 
PDD n=4 
m=55.6% 80.3±1.7 
Mild (3) DLB n=7, 
PDD n=5, 
AD n=3 
m=73.3% 79.9±1.8 
Moderate 
(4) 
DLB n=14, 
PDD n=11, 
AD n=4 
m=55.2% 81.8±1.5 
Severe (5) DLB n=10, 
PDD n=12, 
AD n=8 
m=50% 81.6±1.1 
Age at death is mean ± SEM.
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Figure 1: 19S ATPase RPT6, proteasome sub-unit values, from semi-quantitative Western 
blotting in PDD, DLB, AD, and control in BA9, BA24 and BA40. 
The image is a representative Western blot showing an example of the diagnosis-specific 
reductions of the 19S ATPase RPT6 in BA9 (A), BA24 (B) and BA40 (C). 
Statistical analysis was performed using one-way analysis of variance (ANOVA) and 
Bonferroni post hoc test. BA9 (D): Mean RPT6 values from controls (n = 24) were 
significantly higher than Parkinson’s disease dementia (PDD) (p = 0.001, n = 33), dementia 
with Lewy bodies (DLB) (p = 0.001, n = 50) and AD (p = 0.001, n = 16) groups, one-way 
ANOVA (F = 24.303, d.f. = 3, 119, p = 0.001 followed by Bonferroni post hoc test). BA24 
(E): Mean RPT6 values for the control (n = 24) and PDD (n = 33) groups were significantly 
higher than DLB (p < 0.05, n = 52) and AD (p < 0.05, n = 16) groups. There was no 
difference between the control and PDD groups, one-way ANOVA (F = 13.56, d.f. = 3 and 
113, p = 0.001; Bonferroni post hoc test). BA40 (F): There was no significant difference in 
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RPT6 levels between controls and PDD, but RPT6 levels for the control group (n = 24) and 
PDD (n = 33) groups were significantly higher than DLB (p < 0.05, n = 52) and AD (p = 
0.001, n = 16) groups, one-way ANOVA (F = 16.333, d.f. = 3 and 121, p = 0.001; Bonferroni 
post hoc test). The horizontal bars within the data points in the graphs represent the mean 
values. 
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 Figure 2: Analysis of PGPH-like activities in brain homogenates from BA9, BA40, and 
BA24 of DLB, PDD, AD, and controls.  
Scatter plots are shown of PGPH-like activity measurement in BA9, BA40, and BA24 
homogenates from DLB, PDD, AD, and normal control samples using the fluorogenic 
substrate assay. Activities are expressed as fluorescence units (FU)/mg protein/hour. BA9: 
PGPH-like activity was significantly decreased only in AD patients (p = 0.012, n = 6) 
compared with the control (n = 9); DLB and PDD groups were lower compared with the 
control subjects, but there was no statistically significant difference between them. The 
values for the ANOVA for PGPH-like activity measurement in BA9 were: F = 7.897, d.f. = 3, 
34, p = 0.001). BA40; the differences between the patients’ groups (PDD, DLB and AD) and 
the control were statistically different (one-way ANOVA, F = 10.263, d.f. = 3 and 42, p = 
0.001;). The reduction in PGPH-like activity was higher in the AD group with a mean ± SEM 
value of 3741.8 ± 587.5, n = 11, compared with 1.28 ± 0.028, n = 24 for the controls. The 
reduction in both DLB and PDD were also significant with a mean ± SEM value of 4133.7 ± 
640, n = 10 and 4809 ± 240, n = 9 compared with control (Bonferroni post hoc test). In BA24 
there was a significant difference between DLB (p = 0.013, n = 12), PDD (P = 0.001, n = 9) 
and AD (P = 0.001, n = 9) compared with the control (n = 13) (one-way ANOVA, F = 
23.087, d.f. = 3 and 39, p = 0.001; Bonferroni post hoc test). PGPH-like activity 
27 
 
measurements were significant lower in both AD (p = 0.004, n = 9) and PDD (p = 0.002, n = 
9) compared with DLB subjects. The horizontal bars within the data points in the graphs 
represent the mean values. 
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Figure 3: Analysis of chymotrypsin -like activities in brain homogenates from BA9, BA40, 
and BA24 of DLB, PDD, AD, and controls.  
Scatter plots are shown of chymotrypsin-like activity measurement in BA9, BA40, and BA24 
homogenates from DLB, PDD, AD, and normal control samples using the fluorogenic 
substrate assay. Activities are expressed as fluorescence units (FU)/mg protein/hour. BA9; 
the activities’ values for the control group were significantly higher than the PDD (p = 0.004, 
n = 12), DLB (p = 0.013, n = 11) and AD (p = 0.001, n = 6) groups. The ANOVA values for 
chymotrypsin-like activity measurement in BA9 are: F = 7.897, d.f. = 3 and 34, p = 0.001) 
BA40; the activities’ values for the control group (n =13) were significantly higher than the 
PDD (p = 0.001, n = 10), DLB (p = 0.001, n = 9) and AD (p = 0.001, n = 12) groups. The 
ANOVA for chymotrypsin-like activity measurement in BA40 (one-way ANOVA, F = 
30.033, d.f. = 3 and 40, p = 0.001; Bonferroni post hoc test) BA24; there was a significant 
difference between the PDD (p = 0.015, n = 9) and AD (p = 0.044, n = 9) groups compared 
with the control (n = 13) (one-way ANOVA, F = 4.664, d.f. = 3 and 39, p = 0.007; 
Bonferroni post hoc test). 
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Figure 4: Relationship between RPT6 expression levels and cognitive impairment based 
upon MMSE classification 
19S ATPase RPT6, proteasome sub-unit values protein levels in BA9, BA24 and BA40 
predicted cognitive impairment. Regression analysis showed RPT6 levels in BA9, BA24 and 
BA40 of control, DLB, PDD and AD to be significant predictors of the cognitive impairment 
category ([BA9] R
2
 = 0.297, beta = −0.545, degree of freedom [df] = 1, 102, t = −6.571, p = 
0.001, [BA24] R
2
 = 0.04, beta = −0.206, df = 1, 99, t = −2.09, p = 0.039, [BA40] R2 = 0.180, 
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beta = −0.425, df = 1, 105, t = −4.807, p = 0.001]. The analysis of variance (ANOVA) for the 
model was significant (p = 0.0001). The difference in mean RPT6 levels between cognitive 
impairment groups was analysed by one-way ANOVA and the Bonferroni post hoc test, 
which revealed RPT6 levels in BA9 to be significantly higher in controls compared with the 
other groups (one-way ANOVA F = 17.82, d.f. = 4 and 99, p = 0.001; Bonferroni post hoc 
test). In BA40, RPT6 levels were significantly lower in people with moderate dementia (10%, 
p = 0.033) and with severe dementia (19%, p = 0.001) compared with controls. The 
difference in mean RPT6 levels between cognitive impairment groups in BA24 was not 
found to be significant (one-way ANOVA p > 0.05). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
 
 
32 
 
Figure 5: The relationship between Chymotrypsin- and PGPH-like proteasome activity 
measurement levels and cognitive impairment based upon MMSE classification. 
Chymotrypsin- and PGPH-like proteasome activity measurement levels, using fluorogenic 
substrate assay, predicted cognitive impairment in BA9, BA24, and BA40. 
 Regression analysis showed Chymotrypsin-like and PGPH proteasome activity to be a 
significant predictor of cognitive impairment in BA9 (figure A and D, R
2
 = 0.337, beta = 
−0.581, [df] = 1, 29, t = −3.84, p = 0.001, R2 = 0.275, beta = −0.524, [df] = 1, 29, t = −3.315, 
p = 0.002), in BA24 (figure B and E, R
2
 = 0.151, beta = −0.388, [df] = 1, 38, t = −2.599, p = 
0.013, R
2
 = 0.371, beta = −0.609, [df] = 1, 38, t = −4.733, p = 0.001) and in BA40 (figure C 
and F, R
2
 = 0.531, beta = −0.728, [df] = 1, 40, t = −6.72, p = 0.001, R2 = 0.217, beta = 
−0.466, [df] = 1, 38, t = −3.244, p = 0.002). The difference in mean Chymotrypsin-like and 
PGPH proteasome activity measurement levels between different cognitive impairment 
groups was analysed by one-way ANOVA and the Bonferroni post hoc test, which revealed 
high chymotrypsin-like activity in the controls compared with moderate (p = 0.014) and 
severe scores (p = 0.01) (one-way ANOVA F = 5.009, d.f. = 4 and 26, p = 0.004; Bonferroni 
post hoc test). There was a high PGPH-like activity in unimpaired cognition compared with 
the moderate groups (one-way ANOVA F = 3.616, d.f. = 4 and 26, p = 0.004; Bonferroni 
post hoc test). In BA24, there was higher PGPH-like activity in unimpaired cognition  group 
compared with MCI (p = 0.03), mild (p = 0.024), moderate (p = 0.001) and severe scores (p = 
0.001) (one-way ANOVA F = 9.839, d.f. = 4 and 35, p = 0.001; Bonferroni post hoc test). In 
BA40 the level of chymotrypsin-like activity was significantly higher in the controls 
compared with MCI (p = 0.001), mild (p = 0.001), moderate (p = 0.001) and severe scores (p 
= 0.001) (one-way ANOVA F = 21.845, d.f. = 4 and 37, p = 0.001; Bonferroni post hoc test). 
There was a higher level of PGPH-like activity in unimpaired cognition group compared with 
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MCI (p = 0.02), mild (p = 0.001), moderate (p = 0.001) and severe scores (p = 0.034) (one-
way ANOVA F = 8.851, d.f. = 4 and 35, p = 0.001; Bonferroni post hoc test) 
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Supplementary Figures 
The expression levels of proteasome 20S α3 subunit and 20S α6 subunit were determined 
using semi-quantitative Western blotting as for RPT6 but using a mouse monoclonal IgG IgG 
(MCP257) for α3 (supplementary figure 1) which recognised a very distinct band at 
approximately 29 kDa which is consistent with published size [69] and data sheet from the 
supplier and a mouse monoclonal IgG (MCP20) for α6 (supplementary figure 2) that 
recognised a very distinct band at approximately 28 kDa which is consistent with published 
size [70] and data sheet from the supplier. 
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Supplementary figure 1 
In BA9 the α3 subunit of the 20S proteasome unit was significantly increased in PDD cases 
compared to DLB (U=488, p=0.002) and AD cases (U=227, p=0.01) according to Mann-
Whitney U test. In BA24, PDD cases had significantly lower levels of α3 compared to control 
(U=151, p=0.00014), DLB (U=333, p=0.00001) and AD (U=66, p=0.00002). Control cases 
were significantly lower than AD cases (U=83, p=0.004). In BA40 PDD cases had 
significantly higher levels of α3 compared to control (p=0.001), DLB (p=0.000005) and AD 
(p=0.043) according to one-way ANOVA and Bonferroni post hoc test (F=10.495, df=3,126 
p=0.000003). 
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Supplementary figure 2 
The levels of α6 in BA9 were significantly decreased in AD cases compared to controls 
(U=84, p=0.0002), PDD (U=149.5, p=0.001) and DLB (U=175, p=0.00009). In BA24 the 
levels of α6 were significantly reduced in control cases compared to PDD cases (p=0.002) 
and DLB cases (p=0.007) according to one-way ANOVA and Bonferroni post hoc test 
(F=5.221, df=3,119, p=0.002). In BA40 there was no significant difference in the levels of α6 
between diagnostic groups. 
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Supplementary figure 3 
The ratio of chymotrypsin-like activity to α3 levels was determined for each brain region. In 
BA9 this ratio was significantly higher in control cases compared to DLB and to AD cases 
(U=4, p=0.002) and (U=9, p=0.005). In BA24 there was no significant difference between 
diagnostic groups. In BA40 PDD cases had a significantly lower ratio compared to control 
(p=0.0002) and DLB (p=0.0004) according to one-way ANOVA and Bonferroni post hoc test 
(F=9.102, df=3,40, p=0.0001). 
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Supplementary figure 4 
Likewise, PGPH-like activity was expressed as a ratio to the level of α3. In BA9, this ratio 
was significantly decreased in DLB cases compared to control cases (U=1, p=0.001). In 
BA24 this ratio was significantly lower in PDD cases compared to control (p=0.00006) and 
DLB (0.044) according to one-way ANOVA (F=12.228, df=3,38, p=0.00001). In BA40 
control cases had a significantly higher ratio than PDD (p=0.004), DLB (p=0.032) and AD 
(0.001) according to one-way ANOVA (F=7.502, df=3,39, p=.0004). 
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Supplementary figure 5 
The ratio of chymotrypsin-like activity to the level of α6 subunits in BA9 and in BA40 was 
not significantly different between diagnostic groups. However, in BA24 it was significantly 
higher in control cases compared to PDD and AD cases (p=0.0004 & p=0.018) according to 
one-way ANOVA and bonferroni post hoc-test (F=7.351, df=3,38, p=0.001). 
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Supplementary figure 6 
There was no significant different in the ratio of PGPH-like activity to the level of α6 
subunits in BA9 between diagnostic groups. However, in BA24 this ratio was significantly 
higher in control cases compared to PDD (p=0.00000002), DLB (p=0.003) and AD cases 
(p=0.0000001). DLB cases had a significantly higher ratio compared to PDD (p=0.003) and 
to AD cases (p=0.015), according to one-way ANOVA and bonferroni post-hoc test 
(F=25.475, df=3,38, p=0.000000003). In BA40 this ratio was significantly higher in control 
cases compared to PDD (U=23, p=0.018), DLB (U=25, p=0.013) and AD cases (U=10, 
p=0.0004). 
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